Vestal Point Capital LP Has $53.42 Million Holdings in uniQure (NASDAQ:QURE)

Vestal Point Capital LP reduced its holdings in shares of uniQure (NASDAQ:QURE - Free Report) by 36.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,025,000 shares of the biotechnology company's stock after selling 1,725,000 shares during the period. uniQure accounts for about 3.2% of Vestal Point Capital LP's investment portfolio, making the stock its 8th largest holding. Vestal Point Capital LP owned about 6.21% of uniQure worth $53,422,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of QURE. China Universal Asset Management Co. Ltd. grew its stake in shares of uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after acquiring an additional 969 shares during the last quarter. Tudor Investment Corp ET AL grew its position in uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock valued at $438,000 after purchasing an additional 1,371 shares during the last quarter. Wells Fargo & Company MN grew its position in uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after purchasing an additional 1,503 shares during the last quarter. Northern Trust Corp raised its holdings in uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock worth $1,688,000 after buying an additional 1,923 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in uniQure by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company's stock worth $1,253,000 after buying an additional 3,996 shares during the last quarter. Institutional investors own 78.83% of the company's stock.

Wall Street Analyst Weigh In

QURE has been the subject of a number of recent analyst reports. Guggenheim restated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. Wells Fargo & Company reduced their target price on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Wall Street Zen upgraded uniQure to a "sell" rating in a research note on Tuesday, March 11th. Cantor Fitzgerald raised uniQure to a "strong-buy" rating in a research report on Monday. Finally, HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of uniQure in a research report on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.

Insider Transactions at uniQure

In related news, CFO Christian Klemt sold 2,916 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the sale, the chief financial officer now directly owns 155,168 shares of the company's stock, valued at approximately $1,756,501.76. This represents a 1.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 26,727 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $285,978.90. Following the sale, the chief executive officer now owns 571,188 shares in the company, valued at approximately $6,111,711.60. The trade was a 4.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock worth $961,401 in the last 90 days. 4.74% of the stock is currently owned by insiders.

uniQure Stock Performance

NASDAQ:QURE traded down $0.27 on Thursday, hitting $15.23. The stock had a trading volume of 656,507 shares, compared to its average volume of 1,892,174. The business's 50-day simple moving average is $12.39 and its two-hundred day simple moving average is $12.47. The stock has a market cap of $834.24 million, a price-to-earnings ratio of -3.07 and a beta of 0.10. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. As a group, research analysts predict that uniQure will post -3.75 earnings per share for the current year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.